Novo Holdings A/S’s Crinetics Pharmaceuticals CRNX Stock Holding History

Novo Holdings A/S’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.3M	Sell	1,550,000 -75,000	-5%	-$3.35M	4.56%	7
2025 Q4	$75.6M	Hold	1,625,000	–	–	5.87%	6
2025 Q3	$67.7M	Buy	1,625,000 +75,000	+5%	+$2.4M	4.36%	8
2025 Q2	$44.6M	Buy	1,550,000 +275,000	+22%	+$8.49M	3.15%	9
2025 Q1	$42.8M	Buy	1,275,000 +314,785	+33%	+$11.8M	3.25%	10
2024 Q4	$49.1M	Sell	960,215 -39,785	-4%	-$2.23M	2.97%	11
2024 Q3	$51.1M	Hold	1,000,000	–	–	2.54%	13
2024 Q2	$44.8M	Sell	1,000,000 -98,600	-9%	-$4.55M	2.41%	11
2024 Q1	$51.4M	Sell	1,098,600 -1,400	-0.1%	-$54.8K	3.55%	7
2023 Q4	$39.1M	Hold	1,100,000	–	–	2.42%	16
2023 Q3	$32.7M	Hold	1,100,000	–	–	2.42%	18
2023 Q2	$19.8M	Hold	1,100,000	–	–	1.53%	24
2023 Q1	$17.7M	Buy	1,100,000 +362,943	+49%	+$6.72M	1.17%	25
2022 Q4	$13.5M	Buy	737,057 +105,430	+17%	+$1.86M	0.84%	34
2022 Q3	$12.4M	Hold	631,627	–	–	0.59%	30
2022 Q2	$11.8M	Buy	631,627 +206,730	+49%	+$4.13M	0.58%	32
2022 Q1	$9.33M	Buy	+424,897	New	+$8.6M	0.49%	37
2021 Q2	–	Sell	-271,378	Closed	-$4.15M	–	56
2021 Q1	$4.15M	Hold	271,378	–	–	0.17%	46
2020 Q4	$3.83M	Hold	271,378	–	–	0.16%	43
2020 Q3	$4.25M	Buy	271,378 +56,925	+27%	+$870K	0.21%	41
2020 Q2	$3.76M	Buy	214,453 +50,000	+30%	+$852K	0.24%	32
2020 Q1	$2.42M	Buy	164,453 +29,444	+22%	+$603K	0.16%	28
2019 Q4	$3.39M	Hold	135,009	–	–	0.22%	24
2019 Q3	$2.03M	Hold	135,009	–	–	0.35%	25
2019 Q2	$3.38M	Hold	135,009	–	–	0.47%	25
2019 Q1	$3.07M	Hold	135,009	–	–	0.45%	20
2018 Q4	$4.05M	Sell	135,009 -14,991	-10%	-$422K	0.57%	20
2018 Q3	$4.3M	Buy	+150,000	New	+$4.45M	0.34%	21

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Novo Holdings A/S's CRNX Position: Q1 2026 in Review

Novo Holdings A/S reduced its Crinetics Pharmaceuticals (CRNX) stake by 4.6% in Q1 2026, selling an estimated $3.35M and leaving 1,550,000 shares worth $56.3M. The position accounts for 4.56% of the portfolio, ranked #7.

Novo Holdings A/S first reported a position in CRNX in Q3 2018 and has held it in 28 quarters since. The position peaked at $75.6M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Novo Holdings A/S held 1,550,000 shares of Crinetics Pharmaceuticals worth $56.3M as of Q1 2026.
Novo Holdings A/S sold 75,000 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $3.35M.
Crinetics Pharmaceuticals made up 4.56% of Novo Holdings A/S's portfolio in Q1 2026, its #7 holding.
Novo Holdings A/S first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 28 quarters since.
Novo Holdings A/S's Crinetics Pharmaceuticals position peaked at $75.6M in Q4 2025.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.